Sasha Gentling, CFA Joins BioSig as Director of Business Development
November 06 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “The
Company”), a medical technology company developing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the Company further expanded its
Investor Relations team by appoining Ms. Sasha Gentling, CFA as
Director of Business Development and Investments.
Minnesota based Ms. Gentling becomes the first employee of
BioSig’s Rochester office. Prior to joining the Company, Ms.
Gentling served as Investment Officer at Mayo Clinic, a role, in
which she managed key components of Mayo Clinic’s investment
portfolio, overseeing external manager relationships in absolute
return core credit hedge fund strategies, fixed income, and real
estate private equity, as well as conducting comprehensive due
diligence on potential new investments in both public and private
markets. Prior to that role Ms. Gentling managed investor
communications and marketing activities at Connecticut based
Discerene Group, during which time AUM increased by over $700
million. During the course of her career Ms. Gentling conducted
extensive research for emerging value-oriented hedge funds and
generated investment recommendations by building and maintaining
earnings, valuation models and financial projections. Ms. Gentling
holds an MBA in Finance and Management from Columbia Business
School and a BA in English and Music from Middlebury College.
“We were impressed by Sasha’s investement experience and her
achievements in both profit and non-profit organizations,”
commented Kenneth L. Londoner, Chairman and CEO of BioSig
Technologies, Inc. “Sasha is an excellent addition to our
accomplished business team, and her expertise in managing
endowments, family offices and impact investment groups will be
highly beneficial to our expanding business relationships in the
Midwest.”
“Investment communities are on a constant lookout for value
opportunities, and there is a growing interest in high-potential
life science companies that are aiming to address complex, often
unresolvable clinical needs. It is fascinating just how much goes
on behind the scenes at BioSig, and I look forward to contributing
my knowledge and experience to this rapidly growing innovative
company,” said Ms. Gentling.
BioSig recently appointed Mr. Andrew Ballou as Vice President of
Investor Relations. The Company’s stock was listed on the Nasdaq
Capital Market exchange in September 2018 and was recently added to
the Russell 3000 Index. About BioSig Technologies
BioSig Technologies is a medical technology company developing a
proprietary biomedical signal processing platform designed to
improve the electrophysiology (EP) marketplace (www.biosig.com).
Led by a proven management team and a veteran Board of Directors,
BioSig Technologies is preparing to commercialize its PURE
EPTM System. The technology has been developed to address an unmet
need in a large and growing market.
The Company’s first product, PURE EPTM System is a computerized
system intended for acquiring, digitizing, amplifying, filtering,
measuring and calculating, displaying, recording and storing of
electrocardiographic and intracardiac signals for patients
undergoing electrophysiology (EP) procedures in an EP laboratory.
The system is indicated for use under the supervision of licensed
healthcare practitioners who are responsible for interpreting the
data. This novel cardiac signal acquisition and display system is
engineered to assist electrophysiologists in clinical
decision-making during electrophysiology procedures in patients
with abnormal heart rates and rhythms. BioSig’s ultimate goal is to
deliver technology to improve upon catheter ablation treatments for
the prevalent and potentially deadly arrhythmias, Atrial
Fibrillation and Ventricular Tachycardia. BioSig has partnered with
Minnetronix on technology development and received FDA 510(k)
clearance for the PURE EP EPTM System in August 2018.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes
in the size and nature of our competition; (iv) loss of one or more
key executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024